Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TT-10 + TT-4 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TT-10 | TT10|TT 10 | Adenosine Targeting 25 | TT-10 acts as an antagonist to the adenosine receptor A2AR, potentially leading to inhibition of tumor growth and enhanced antitumor immune response (Cancer Res (2022) 82 (12_Supplement): 3454) | |
| TT-4 | TT4|TT 4|PORT7|PORT-7|PORT 7 | Adenosine Targeting 25 | TT-4 acts as an antagonist to the adenosine receptor A2BR, which potentially inhibits tumor growth and induces antitumor immune response (Cancer Res (2022) 82 (12_Supplement): 3454). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04969315 | Phase Ib/II | TT-10 + TT-4 TT-4 TT-10 | TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma | Recruiting | USA | 0 |